Rigel Pharmaceuticals, Inc. (RIGL) News
Filter RIGL News Items
RIGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RIGL News Highlights
- RIGL's 30 day story count now stands at 4.
- Over the past 10 days, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RIGL are MD and BRSP.
Latest RIGL News From Around the Web
Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Catapults 44% Though Its Price And Business Still Lag The IndustryRigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great... |
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are up 20% this past week, but still in the red over the last three yearsThis month, we saw the Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) up an impressive 56%. But that is small recompense... |
Best Momentum Stock to Buy for December 8thBRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023. |
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other CancersRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. |
Best Momentum Stocks to Buy for November 22ndBWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023. |
New Strong Buy Stocks for November 22ndRIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023. |
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call TranscriptRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call Transcript November 7, 2023 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.07. Operator: Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the Third Quarter of 2023. At this time, all participants are in listen-only mode. A brief question-and-answer session will […] |
Rigel Pharmaceuticals Inc (RIGL) Reports Q3 2023 Financial Results: A Step Towards Financial ...Record TAVALISSE Sales and Expense Discipline Drive Progress |
Rigel Reports Third Quarter 2023 Financial Results and Provides Business UpdateRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2023, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA® (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible iso |
Rigel to Present at the Jefferies London Healthcare ConferenceRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies 2023 London Healthcare Conference on Tuesday, November 14, 2023 at 3:30 p.m. GMT (10:30 a.m. EST). |